Recordati : ZAN-EXTRA? APPROUV? EN AUSTRALIE

Milan, le 20 février 2008 - Recordati a annoncé l'approbation de Zan-Extra, une combinaison fixe de lercanidipine et d'énalapril pour le traitement de l'hypertension, en Australie. L'Australian Register of Therapeutic Goods (ARTG) a fait connaître son accord pour l'enregistrement du médicament Zan-Extra®, soumis par le titulaire de la licence Solvay Biosciences, qui existe sous deux formes de dosage : lercanidipine 10mg/énalapril 10mg et lercanidipine 10mg/énalapril 20mg. Le lancement de ce nouveau produit de Recordati est prévu en Australie au mois avril.


"Cette approbation en Australie représente une étape supplémentaire dans le développement de notre nouveau produit antihypertenseur suite à son lancement en Allemagne en 2007 " a déclaré le PDG Giovanni Recordati. " Lercanidipine est déjà un succès sur ce marché (23 %), 4ème au monde et 1er hors d'Europe, et peut voir sa position s'améliorer grâce à cette nouvelle combinaison " a ajouté Giovanni Recordati. Nous attendons sous peu le résultat de la procédure de reconnaissance mutuelle en Europe et ceci nous permettra de lancer le produit en Europe.

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), dedicated to the research, development, manufacturing and marketing of pharmaceuticals, with headquarters in Milan, Italy, operations in the main European countries, and a total staff of over 2,200. A European field force of over 1,100 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas. Recordati's current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations. Recordati is committed to the research of new drug entities within the cardiovascular and urogenital therapeutic areas in which its research team has proven scientific competence and a track record of discovery and development of original drugs, the most recent of which, lercanidipine, a latest generation calcium channel blocker for the treatment of hypertension, is the company's leading product. Consolidated revenue for 2007 was E 628.4 million, operating income was E 131.5 million and net income was E 84.9 million.

For further information:

Recordati website: www.recordati.com

Investor Relations
Marianne Tatschke
(39)0248787393
e-mail: [email protected]

Media Relations
Claudio Rossetti (Echo Comunicazione d'Impresa)
(39)02 62694736
e-mail: [email protected]

Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.

Copyright Hugin